Bitter Backlash Greets Wider Medicare Drug Negotiations
A Trump administration bid to boost Medicare's negotiating power with drugmakers is facing an onslaught of attacks, including veiled threats of litigation by the pharmaceutical lobby, newly released letters show....To view the full article, register now.
Already a subscriber? Click here to view full article